Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 225

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Inclisiran and cardiovascular events: a patient-level analysis of phase III trials

Open access
Ray, Kausik K, Raal, Frederick J, Kallend, David G, Jaros, Mark J, Koenig, Wolfgang, Leiter, Lawrence A, Landmesser, Ulf, Schwartz, Gregory G, Lawrence, David, Friedman, Andrew, Garcia Conde, Lorena, Wright, R Scott, ORION Phase III investigators · 2023 · European Heart Journal

Abstract

Background: Inclisiran, an siRNA administered twice-yearly, significantly reduced LDL cholesterol (LDL-C) in Phase III trials. Whether lowering LDL-C with inclisiran translates into a lower risk of cardiovascular (CV) events is not yet established. Methods and results: Patient-level, pooled analysis of ORION-9, −10 and −11, included patients with heterozygous familial hypercholesterolaemia, atherosclerotic CV disease (ASCVD), or ASCVD risk equivalent on maximally tolerated statin-therapy, randomized 1:1 to receive 284 mg inclisiran or placebo on Days 1, 90, and 6-monthly thereafter for 18 months. Prespecified exploratory endpoint of major cardiovascular events (MACEs) included non-adjudicated CV death, cardiac arrest, non-fatal myocardial infarction (MI), and fatal and non-fatal stroke, evaluated as part of safety assessments using a standard Medical Dictionary for Regulatory Activities basket. Although not prespecified, total fatal and non-fatal MI, and stroke were also evaluated. Mean LDL-C at baseline was 2.88 mmol/L. At Day 90, the placebo-corrected percentage reduction in LDL-C with inclisiran was 50.6%, corresponding to an absolute reduction of 1.37 mmol/L (both P < 0.0001). Among 3655 patients over 18 months, 303 (8.3%) experienced MACE, including 74 (2.0%) fatal and non-fatal MIs, and 28 (0.8%) fatal and non-fatal strokes. Inclisiran significantly reduced composite MACE [OR (95% CI): 0.74 (0.58–0.94)], but not fatal and non-fatal MIs [OR (95% CI): 0.80 (0.50–1.27)] or fatal and non-fatal stroke [OR (95% CI): 0.86 (0.41–1.81)]. Conclusion: This analysis offers early insights into the potential CV benefits of lowering LDL-C with inclisiran and suggests potential benefits for MACE reduction. These findings await confirmation in the larger CV outcomes trials of longer duration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehac594

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 8

  1. Ference, 2019, Mendelian Randomization study of ACLY and cardiovascular disease, N Engl J Med, 380, 1033, 10.1056/NEJMoa1806747 · DOI · Paper page
  2. Najam, 2015, The past, present and future of lipid lowering therapy, Clin Lipidol, 10, 481, 10.2217/clp.15.40 · DOI
  3. Macchi, 2019, A new Dawn for managing dyslipidemias: the era of RNA-based therapies, Pharmacol Res, 150, 104413, 10.1016/j.phrs.2019.104413 · DOI
  4. Wright, 2021, Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis, J Am Coll Cardiol, 77, 1182, 10.1016/j.jacc.2020.12.058 · DOI · Paper page
  5. Ference, 2018, Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the cholesterol treatment trialists collaboration, Eur Heart J, 39, 2540, 10.1093/eurheartj/ehx450 · DOI · Paper page
  6. Steg, 2019, Effect of alirocumab on mortality after acute coronary syndromes, Circulation, 140, 103, 10.1161/CIRCULATIONAHA.118.038840 · DOI
  7. Gaba, 2021, Comparative reductions in investigator-reported and adjudicated ischemic events in REDUCE-IT, J Am Coll Cardiol, 78, 1525, 10.1016/j.jacc.2021.08.009 · DOI
  8. Easton, 2019, Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial, Int J Stroke, 14, 908, 10.1177/1747493019851282 · doi:10.1177/1747493019851282

Cited by

See all 225

Metadata

Authors
Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M. J., Koenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Lawrence, D., Friedman, A., Garcia Conde, L., Wright, R. S., & ORION Phase III investigators
Venue
European Heart Journal
Published
2022-11-04
Volume
44
Issue
2
Pages
129-138
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4308184058
Cited by
225
References
15
FWCI
38.57
Type
journal article
Language
en
Open access
hybrid
Funders
Novartis Pharma AG

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. https://app.cochat.ai/papers/10.1093/eurheartj/ehac594
The paper
Ray, K. K., Raal, F. J., Kallend, D. G., Jaros, M. J., Koenig, W., Leiter, L. A., Landmesser, U., Schwartz, G. G., Lawrence, D., Friedman, A., Garcia Conde, L., Wright, R. S., & ORION Phase III investigators. (2023). Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. European Heart Journal. https://doi.org/10.1093/eurheartj/ehac594

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.